Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Rutkowski, Jacek
Saad, Everardo D.
Buyse, Marc E.
Jassem, Jacek
机构：
[1] Med Univ Gdansk, Gdansk, Poland
[2] Dendrix Res, Sao Paulo, Brazil
[3] Int Inst Drug Dev, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supll.e20580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20580
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).
    Sjoquist, Katrin Marie
    Lee, Chee
    Lord, Sally
    Chatfield, Mark D.
    Friedlander, Michael
    Simes, John
    Marschner, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, Louise
    Chouaid, Christos
    Vergnenegre, Alain
    Bischoff, Helge
    Walzer, Stefan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1447 - S1448
  • [5] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, L.
    De Castro Carpeno, J.
    Chouaid, C.
    Vergnenegre, A.
    Bischoff, H. G.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A177 - A178
  • [6] Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC
    Rutkowski, Jacek
    Saad, Everardo D.
    Burzykowski, Tomasz
    Buyse, Marc
    Jassem, Jacek
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1619 - 1627
  • [7] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [8] Impact of clinical and biological markers on progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell cancer (NSCLC) treated by erlotinib: results of the ERMETIC cohort
    Cadranel, Jacques
    Lizard, Sarah
    Mauguen, Audrey
    Beau-Faller, Michele
    Friard, Sylvie
    Buisine, Marie-Pierre
    Pretet, Jean-luc
    Degeorges, Armelle
    Madelaine, Jeannick
    Chouaid, Christos
    Morin, Franck
    Pignon, Jean-Pierre
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S502 - S503
  • [9] PROGRESSION-FREE SURVIVAL IS A POOR SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN THE FIRST LINE EGFR-TKI TREATMENT IN ADVANCED NON-SMALL-CELL LUNG CANCER WITH EGFR MUTATION
    Liao, Ri-Qiang
    Yang, Xue-Ning
    Yan, Hong-Hong
    Zhou, Qing
    Wu, Yi-Long
    Zhong, Wen Zhao
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S615 - S615
  • [10] Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer
    Eleazar Omar Macedo-Pérez
    Vicente Morales-Oyarvide
    Víctor Osvaldo Mendoza-García
    Yuzmiren Dorantes-Gallareta
    Diana Flores-Estrada
    Oscar Arrieta
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 681 - 690
12345